Please login to the form below

Not currently logged in
Email:
Password:

Novimmune appoints Guillaume de Sampaïo

He brings experience from Roche, Novartis and Actelion to the Swiss biotech 

Swiss biotech Novimmune has appointed Guillaume de Sampaïo as global head of project management in a role that will also see him sit on its senior management team.

De Sampaïo has 15 years experience in life sciences, having previously served at the likes of Roche, Novartis and Actelion.

Prior to joining Novimmune he served at Danish biotech firm Forward Pharma, where he created and managed its clinical development group.

During that time he contributed to the development of the company's clinical trial portfolio and the facilitation of its successful US IPO during 2014. 

Novimmune chairman and CEO Eduard Holdener said: “With the progression of our R&D pipeline, project management becomes increasingly a crucial element in supporting our growth strategy. 

“Guillaume de Sampaïo will help us to further advance Novimmune as we move closer to the market with our lead program, NI-0501.”

30th November 2016

From: Research

Share

Tags

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
ROAD

ROAD is a digital PR and communications consultancy specialising in promoting the innovators that shape our future health and wellbeing....

Latest intelligence

Mistrust in medical research: a patient perspective
The recent development of several COVID-19 vaccines has placed medical research firmly in the spotlight, highlighting public confusion and misinformation about clinical trials. Patient advocate, Trishna Bharadia reveals what the...
Real-world evidence: breaking boundaries in rare disease
Generating data for drug launches is a challenging process. In rare diseases, with small patient populations and high unmet need, evidence generation is even more complex. Consultant Sarah Poole and...
The heavy toll of COVID-19 on cancer patients
We all know that finding and treating cancer early saves lives. During the COVID-19 pandemic, oncology treatments paused while cancer continued to spread. So, what has been the impact of...

Infographics